Kinnevik Investment


Babylon goes the SPAC route, Kinnevik to book SEK1.8bn in excess value

03/06/21 -"Following the holding company’s 31 May ad hoc announcement regarding a potential listing of Babylon Health, Kinnevik has just confirmed that the company will go public through a SPAC merger ..."

Pages
64
Language
English
Published on
03/06/21
You may also be interested by these reports :
28/08/26
Ackermans & van Haaren delivered a very strong H1-26, with net profit up 24% yoy to c. €340m and core business contribution up 13%. Management ...

28/08/26
As would be expected the Swiss way of managing money cannot be in abstraction from world markets. The ytd performance in Euro of the 5 Swiss stocks ...

27/08/26
We have revised our forward EPS estimates down, primarily for two reasons. First, we have revised down our assumptions for gains on Tencent ...

25/08/26
The AlphaValue UK coverage (63 issuers; €3.1Tn market cap) is a surprising outperformer on a country basis. This universe gained 19% ytd vs. 13% for ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO